logo

MTNB

Matinas Biopharma·AMEX
--
--(--)
--
--(--)
4.19 / 10
Netural

MTNB's fundamental score stands at 4.2/10, indicating balanced but not outstanding business health. Key strengths include a solid Interest coverage ratio (15.48) and positive Revenue-MV difference (-0.257), which suggest adequate profitability and relative valuation appeal. However, challenges such as Days sales outstanding (72.55) in Group 2 and Asset-MV (-0.501) in Group 4 highlight inefficiencies in receivable collection and asset utilization, warranting monitoring. Overall, the company shows guarded potential with room for operational improvement.

Fundamental(4.19)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score3/3
Weight20.17%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.72%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.22%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight16.08%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight16.10%
1M Return8.45%
PB-ROE
Value-0.06
Score3/3
Weight21.80%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.61%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.66%
1M Return0.43%
Asset-MV
Value-0.50
Score0/3
Weight11.48%
1M Return5.75%
Cash-MV
Value-0.07
Score2/3
Weight15.81%
1M Return8.41%
Is MTNB fundamentally strong?
  • MTNB scores 4.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -128.84% ROE, 0.00% net margin, -0.19 P/E ratio, 0.51 P/B ratio, and 24.34% earnings growth, these metrics solidify its Netural investment rating.